Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-12T08:22:28.733Z Has data issue: false hasContentIssue false
  • English
  • Français

Acute Effects of Fluoxetine Versus Placebo on Functional Health and Well-Being in Late-Life Depression

Published online by Cambridge University Press:  07 January 2005

John H. Heiligenstein ,
John E. Ware, Jr ,
Kathy M. Beusterien ,
Paul J. Roback ,
Carol Andrejasich  and
Gary D. Tollefson
John H. Heiligenstein
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A.
John E. Ware, Jr
Affiliation:
Health Technology Associates, Inc., Washington, DC, U.S.A.
Kathy M. Beusterien
Affiliation:
Health Technology Associates, Inc., Washington, DC, U.S.A.
Paul J. Roback
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A.
Carol Andrejasich
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A.
Gary D. Tollefson
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, U.S.A.
Get access

Abstract

In a randomized 6-week trial comparing fluoxetine with placebo, the Medical Outcomes Study 36-Item Short-Form Health Status Survey (SF-36) scales were used to measure the effects of treatment on functional health and well-being among elderly (age ≥ 60 years) outpatients with major depression. In the fluoxetine and placebo groups, 261 and 271 patients, respectively, completed the SF-36 before treatment and at Weeks 3 and 6. Compared with national norms for individuals over age 60, study patients before treatment exhibited baseline decrements on the following SF-36 scales: mental health, role limitations due to emotional problems, social functioning, vitality, role limitations due to physical problems, and bodily pain. Analyses of SF-36 changed scores from baseline to Week 6 revealed that the fluoxetine group improved more than the placebo group across all scales. Differences in changes of scores between groups were significant (p < .05), favoring the fluoxetine group for the scales of mental health, role limitations due to emotional problems, physical functioning, and bodily pain. Improvements observed in the fluoxetine group were both clinically and socially significant.

Type
Introduction
Information
International Psychogeriatrics , Volume 7 , Issue S1 , October 1995 , pp. 125 - 137
Copyright
© 1995 Springer Publishing Company

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)